# Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

> **NCT03844750** · PHASE2 · TERMINATED · sponsor: **Chloe Atreya, MD, PhD** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Liver
- Stage IV Colorectal Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8

## Interventions

- **PROCEDURE:** Hepatectomy
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Vactosertib

## Key facts

- **NCT ID:** NCT03844750
- **Lead sponsor:** Chloe Atreya, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-22
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844750, "Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT03844750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*